106941-22-4

Basic information

• Product Name: Benzenemethanamine, 4-amino-3-iodo-
• CAS NO: 106941-22-4
• Molecular Formula: C7H9IN2
• Molecular Weight: 248.066
• Mol File: 106941-22-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenemethanamine, 4-amino-3-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 4-amino-3-iodo-(106941-22-4)
• EPA Substance Registry System: Benzenemethanamine, 4-amino-3-iodo-(106941-22-4)

Safety Data

• Hazardous Substances Data: 106941-22-4(Hazardous Substances Data)

Upstream product

• 220298-96-4 4‐(tert‐butoxycarbonylamino)benzylamine 
• 873-74-5 4-Aminobenzonitrile 
• 33348-34-4 4-amino-3-iodobenzonitrile 
• 4403-71-8 (4-aminomethyl)aniline 

Downstream Products

• 687635-90-1 N,N''-bis-tert-butyloxycarbonyl-N'-[4-(N,N''-bis-tert-butyloxycarbonylguanidino)-3-iodobenzyl]guanidine 
• 152918-49-5 O-tert-butyl-4-amino-3-iodobenzylcarbamate 
• 911124-97-5 tert-butyl 3-iodo-4-(methylsulfonamido)benzylcarbamate 

Relevant articles and documents

Molecular Scaffolds as Double-Targeting Agents For the Diagnosis and Treatment of Neuroblastoma

The selective delivery of therapeutic and imaging agents to tumoral cells has been postulated as one of the most important challenges in the nanomedicine field. Meta-iodobenzilguanidine (MIBG) is widely used for the diagnosis of neuroblastoma (NB) due to its strong affinity for the norepinephrine transporter (NET), usually overexpressed on the membrane of malignant cells. Herein, a family of novel Y-shaped scaffolds has been synthesized, which have structural analogues of MIBG covalently attached at each end of the Y-structure. The cellular uptake capacity of these double-targeting ligands has been evaluated in vitro and in vivo, yielding one specific Y-shaped structure that is able to be engulfed by the malignant cells, and accumulates in the tumoral tissue, at significantly higher levels than the structure containing only one single targeting agent. This Y-shaped ligand can provide a powerful tool for the current treatment and diagnosis of this disease.

Structure-Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists

Adenosine analogues modified at the 5'-position as uronamides and/or as N6-benzyl derivatives were synthesized.These derivatives were examined for affinity in radioligand binding assays at the newly discovered rat brain A3 adenosine receptor and at rat brain A1 and A2a receptors. 5'-Uronamide substituents favored A3 selectivity in the order N-methyl > N-ethyl ca. unsubstituted carboxamide > N-cyclopropyl. 5'-(N-Methylcarboxamido)-N6-benzyladenosine was 37-56-fold more selective for A3 receptors.Potency at A3 receptors was enhanced upon substitution of the benzyl substituent with nitro and other groups. 5'-N-Methyluronamides and N6-(3-substitutedbenzyl)adenosines are optimal for potency and selectivity at A3 receptors.A series of 3-(halobenzyl)-5'-N-ethyluronamide derivatives showed the order of potency at A1 and A2a receptors of I ca.Br > Cl > F.At A3 receptors the 3-F derivative was weaker than the other halo derivatives. 5'-N-Methyl-N6-(3-iodobenzyl)adenosine displayed a Ki value of 1.1 nM at A3 receptors and selectivity versus A1 and A2a receptors of 50-fold.A series of methoxybenzyl derivatives showed that a 4-methoxy group best favored A3 selectivity.A 4-sulfobenzyl derivative was a specific ligand at A3 receptors of moderate potency.An aryl amino derivative was prepared as a probe for radioiodination and receptor cross-linking.